Table A8.
Descriptive statistics of acrylamide biomarker levels per study and year (adults II).
| Study | Pop | Year | Sample | Mean | SD | Geom. Mean | Min | Max | Median | q10 | q25 | q75 | q90 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FR-ESTEBAN | 36 | 2014 | AAMA | 70.72 | 34.64 | 63.64 | 28.74 | 182.77 | 61.75 | 35.65 | 48.59 | 76.94 | 126.40 |
| FR-ESTEBAN | 138 | 2015 | AAMA | 97.02 | 78.81 | 76.77 | 17.88 | 493.12 | 69.05 | 37.07 | 49.66 | 120.35 | 200.83 |
| FR-ESTEBAN | 23 | 2016 | AAMA | 82.40 | 55.11 | 68.23 | 16.02 | 257.73 | 69.79 | 35.03 | 43.25 | 95.25 | 141.77 |
| FR-ESTEBAN | 36 | 2014 | GAMA | 8.71 | 4.15 | 7.89 | 4.11 | 21.38 | 7.44 | 4.62 | 5.80 | 10.88 | 14.02 |
| FR-ESTEBAN | 138 | 2015 | GAMA | 11.54 | 9.89 | 9.47 | 2.18 | 88.30 | 8.51 | 4.85 | 6.88 | 13.30 | 20.40 |
| FR-ESTEBAN | 23 | 2016 | GAMA | 10.60 | 5.24 | 9.59 | 4.35 | 28.39 | 9.66 | 5.95 | 7.08 | 12.55 | 16.20 |
| LU-LNS+LIH | 34 | 2016 | AAMA | 37.01 | 30.90 | 29.75 | 12.23 | 169.78 | 24.30 | 15.14 | 19.71 | 42.14 | 70.68 |
| LU-LNS+LIH | 123 | 2017 | AAMA | 35.19 | 40.26 | 28.14 | 6.17 | 413.73 | 24.91 | 15.51 | 19.92 | 37.33 | 56.09 |
| LU-LNS+LIH | 34 | 2016 | GAMA | 7.07 | 4.06 | 6.38 | 3.54 | 24.82 | 6.07 | 4.09 | 4.85 | 7.64 | 10.11 |
| LU-LNS+LIH | 123 | 2017 | GAMA | 7.27 | 6.22 | 6.08 | 1.73 | 43.50 | 5.80 | 3.53 | 4.42 | 7.36 | 11.42 |
| POR-INSEF | 62 | 2019 | AAMA | 157.77 | 102.16 | 130.06 | 26.38 | 675.61 | 143.10 | 56.39 | 92.37 | 203.73 | 260.07 |
| POR-INSEF | 9 | 2020 | AAMA | 251.27 | 183.23 | 191.88 | 53.38 | 632.07 | 138.92 | 104.06 | 121.69 | 386.56 | 481.49 |
| POR-INSEF | 62 | 2019 | GAMA | 39.79 | 19.85 | 36.41 | 13.09 | 148.00 | 36.98 | 23.62 | 28.68 | 44.04 | 52.03 |
| POR-INSEF | 9 | 2020 | GAMA | 48.30 | 30.76 | 40.51 | 17.97 | 120.71 | 39.30 | 21.11 | 26.98 | 63.78 | 80.91 |